Geron amends Pharmakon loan to access extra $125M through July 2026

 

Geron posts Q4 2025 EPS -$0.05, revenue $48.0M, misses estimates, amends Pharmakon loan to access extra $125M through July 2026

• Amended Pharmakon loan, disclosed on Q4 2025 earnings call, extends access to an additional $125 million through July 2026.
• Plans February 2026 filing of new shelf registration and ATM program to maintain financial flexibility.
• December 2025 workforce reduction affected about one-third of employees, disclosed alongside Q4 and full-year 2025 results.
• Company issues 2026 guidance for $220–$240 million in RYTELO revenue.
• Geron forecasts 2026 operating expenses of $230–$240 million.

https://finviz.com/quote.ashx?t=GERN&p=d